The Pharma Data

MARCH 31, 2022

650 million fixed rate notes, due April 2029, bearing interest at an annual rate of 1.250%. “We continue to make progress in our environmental, social and governance activities that are an essential part of our strategy and embedded into our business.”.

Treatment 52

Treatment Government Vaccine Disease 52

The Pharma Data

FEBRUARY 22, 2022

Amgen (NASDAQ:AMGN) today announced the issuance of its inaugural $750 million green bond, with a 3.000% semi-annual coupon and maturing in 2029, to advance the environmental goals that are part of Amgen’s environmental, social and governance (ESG) framework.

Government 52

Government International Production Science 52

H1 Blog

MARCH 28, 2023

billion by 2029. The United States devotes roughly $200 billion to national health expenditures on medical devices every year. In fact, the global medical devices market is projected to grow from $495.46 billion in 2022 to $718.92

Production 52

Production Marketing Treatment Hospitals 52

FDA Law Blog: Biosimilars

OCTOBER 13, 2024

This bill would extend the designation deadline until September 30, 2029, a five-year extension (and would require yet another GAO report). It was shortly thereafter introduced in the Senate and referred to the Committee on Health Education, Labor, and Pensions, where it remains.

Disease 64

Disease FDA FDA Approval Government 64

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. Phase-Ins : To ease the transition to 10% and 20% discounts, the IRA has two phase-in programs for certain manufacturers. had Part D expenditures on or before August 16, 2022).

Compliance 105

Compliance Drugs Pharmacy Licensing 105

The Pharma Data

OCTOBER 9, 2021

Bristol Myers Squibb continues to expect greater than $4 billion non-risk adjusted revenue target for deucravacitinib in 2029. The company will complete a full review of the data from LATTICE-UC and the potential of deucravacitinib in UC continues to be evaluated in IM011-127, a second Phase 2 trial that also includes a higher dose.

Disease 52

Disease Trials Science Immune Response 52

The Pharma Data

SEPTEMBER 27, 2021

3.375% Notes due 2029 532457 BV9 12 1.250% due August 15, 2031 1.321% 15 bps $1,130.16 Treasury Security Reference Yield Fixed Spread Total Consideration (1)(2) 4.150% Notes due 2059 532457 BU1 1 (3) 2.375% due May 15, 2051 1.865% 80 bps $1,347.88 3.950% Notes due 2049 532457 BT4 2 (4) 2.375% due May 15, 2051 1.865% 70 bps $1,268.49

Disease 52

Disease Marketing 52

The Pharma Data

SEPTEMBER 7, 2021

3.375% Notes due 2029. 360,745,000. 1.750% due August 15, 2041. 3.700% Notes due 2045. 532457 BJ6. 412,467,000. 2.375% due May 15, 2051. 532457 BV9. 1,150,000,000. 1.250% due August 15, 2031. 3.100% Notes due 2027. 532457 BP2. 401,450,000. 0.750% due August 31, 2026. 2.750% Notes due 2025. 532457 BH0. 560,646,000.

Licensing 52

Licensing Licensing Marketing 52

The Pharma Data

JANUARY 25, 2021

Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Marketing 52

Marketing Disease Clinical Trials Clinical Development 52

Vial

MARCH 1, 2024

billion by 2029. The growing demand for CRO services is fueled by the high costs of in-house drug discovery and development, the increasing number of products in the development pipeline, tech advancements, and the growing focus on precision and personalized medicine. from 2024 to reach US$129.8

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

The Pharma Data

SEPTEMBER 27, 2021

Acceptance Priority Level Principal Amount Outstanding Principal Amount Tendered Approximate Percentage of Outstanding Amount Tendered Anticipated Principal Amount to be Accepted for Purchase 4.150% Notes due 2059 532457 BU1 1 (1) $1,000,000,000 $408,714,000 40.87% $408,714,000 3.950% Notes due 2049 532457 BT4 2 (2) $1,500,000,000 $541,847,000 36.12% (..)

Marketing 40

Marketing Disease 40

Broad Institute

AUGUST 2, 2023

at Harvard University in 2029, where he is pursuing a PhD in Economics and Health Policy. The Sabatini Lab focuses on the development and regulation of synapses in the brain and the relationship of these processes to behavior and disease.

Medical Schools 52

Medical Schools Disease Science International 52

Agency IQ

NOVEMBER 27, 2023

BY RAYAN BHARGAVA, MSC | NOV 17, 2023 4:53 PM CST Regulatory background The European Partnership for the Assessment of Risks from Chemicals (PARC) is the seven year program, lasting from 2022 to 2029, which aims to facilitate, share, and improve research on chemical risk assessment.

Animal Testing 40

Animal Testing Research Regulations Compliance 40

Agency IQ

JANUARY 26, 2024

MDR Article 78(14) sets out the original transition deadline in going from voluntary use of the coordinated assessment process to mandatory use as May 25, 2027; for IVDs, use of the coordinated procedure becomes mandatory in May 26, 2029 for all Member States, as set out in IVDR Article 74(14).

Regulations 40

Regulations Compliance Laboratories Production 40

Agency IQ

MAY 28, 2024

The Commission is mandated under the DWD to report by January 12, 2029, and “where appropriate thereafter […] on the potential threat to sources of water intended for human consumption from microplastics, pharmaceuticals and, if necessary, other contaminants of emerging concern, and on the relevant associated potential health risks.”

Compliance 40

Compliance Production Pharmaceuticals Treatment 40

Agency IQ

MAY 10, 2024

By 2029, this will include artificial turf as well as outdoor apparel for severe weather conditions (unless it is accompanied by a specific warning statement).

Packaging 40

Packaging Regulations Production Compliance 40

Agency IQ

FEBRUARY 2, 2024

However, the extension would also limit certain updates to these IVDs. To qualify, the devices must continue to comply with the IVDD, cannot undergo any significant design or use changes, and cannot present “an unacceptable risk to health or safety.”

FDA 40

FDA Laboratories Regulations Production 40